Pictilisib, an investigational pan-class I PI3K inhibitor, also known as GDC-094, has been used in several phase I and II trials for combination therapy of advanced breast cancer and other solid tumors [[36], [37], [38]]. The gene discussed is PIK3CA; the disease is breast cancer.